Aktis Oncology Statistics
Total Valuation
Aktis Oncology has a market cap or net worth of $1.18 billion. The enterprise value is $959.93 million.
Important Dates
The next estimated earnings date is Tuesday, May 12, 2026, before market open.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Aktis Oncology has 55.28 million shares outstanding. The number of shares has increased by 32.24% in one year.
| Current Share Class | 53.40M |
| Shares Outstanding | 55.28M |
| Shares Change (YoY) | +32.24% |
| Shares Change (QoQ) | +10.72% |
| Owned by Insiders (%) | 0.46% |
| Owned by Institutions (%) | 14.85% |
| Float | 26.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 180.88 |
| Forward PS | 58.33 |
| PB Ratio | 6.28 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 147.75 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.37, with a Debt / Equity ratio of 0.06.
| Current Ratio | 7.37 |
| Quick Ratio | 7.30 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -29.45% and return on invested capital (ROIC) is -20.45%.
| Return on Equity (ROE) | -29.45% |
| Return on Assets (ROA) | -15.79% |
| Return on Invested Capital (ROIC) | -20.45% |
| Return on Capital Employed (ROCE) | -31.96% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $82,241 |
| Profits Per Employee | -$806,722 |
| Employee Count | 79 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 18.72 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 61.93 |
| Average Volume (20 Days) | 346,616 |
Short Selling Information
The latest short interest is 2.34 million, so 4.24% of the outstanding shares have been sold short.
| Short Interest | 2.34M |
| Short Previous Month | 2.32M |
| Short % of Shares Out | 4.24% |
| Short % of Float | 8.88% |
| Short Ratio (days to cover) | 4.24 |
Income Statement
In the last 12 months, Aktis Oncology had revenue of $6.50 million and -$63.73 million in losses. Loss per share was -$78.34.
| Revenue | 6.50M |
| Gross Profit | -60.95M |
| Operating Income | -74.68M |
| Pretax Income | -63.73M |
| Net Income | -63.73M |
| EBITDA | -72.36M |
| EBIT | -74.68M |
| Loss Per Share | -$78.34 |
Full Income StatementBalance Sheet
The company has $226.79 million in cash and $11.55 million in debt, with a net cash position of $215.24 million or $3.89 per share.
| Cash & Cash Equivalents | 226.79M |
| Total Debt | 11.55M |
| Net Cash | 215.24M |
| Net Cash Per Share | $3.89 |
| Equity (Book Value) | 187.26M |
| Book Value Per Share | -159.68 |
| Working Capital | 199.07M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$64.13 million and capital expenditures -$9.58 million, giving a free cash flow of -$73.71 million.
| Operating Cash Flow | -64.13M |
| Capital Expenditures | -9.58M |
| Depreciation & Amortization | 2.33M |
| Net Borrowing | n/a |
| Free Cash Flow | -73.71M |
| FCF Per Share | -$1.33 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,149.52% |
| Pretax Margin | -980.93% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Aktis Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -32.24% |
| Shareholder Yield | -32.24% |
| Earnings Yield | -5.42% |
| FCF Yield | -6.27% |
Analyst Forecast
The average price target for Aktis Oncology is $31.50, which is 48.17% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $31.50 |
| Price Target Difference | 48.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Aktis Oncology has an Altman Z-Score of -0.83. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.83 |
| Piotroski F-Score | n/a |
